Asset profile

Bitopertin

Small molecule

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Phase 3underway

Evidence outlook · registrational

Erythropoietic Protoporphyria: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. The registry's posted readout date (2026-09) has passed without a status update. Check News for topline announcements.

How the evidence outlook works ↗

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (1)
June 2028 (1)
Phase 2/3Erythropoietic ProtoporphyriaEnrolling by invitation
Est. primary completion 2028-06 · NCT05883748 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (7)
Phase 2/3 (1)
Phase 2 (5)
Phase 1/2 (1)
Phase 1 (14)